SMMT vs. TEVA: Summit Therapeutics vs. Teva Pharmaceutical Stock Comparison

Company Profile

Summit Therapeutics (SMMT) and Teva Pharmaceutical (TEVA) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but SMMT is classified in Biotechnology while TEVA is classified in Pharmaceuticals.

Summit Therapeutics (SMMT) trades as ordinary local shares, while Teva Pharmaceutical (TEVA) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Summit Therapeutics (SMMT) reports a negative beta of -1.51, suggesting inverse market sensitivity over the measurement window. That is uncommon for ordinary equities and can reflect commodity-linked or hedge-like exposure, but it can also come from statistical noise. Teva Pharmaceutical (TEVA) has a non-negative beta of 0.96.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Summit Therapeutics (SMMT) reports a negative ROE of -220.01%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Teva Pharmaceutical (TEVA) reports 6.65%, ranking against industry peers normally.

Both Summit Therapeutics (SMMT) at 0.00% and Teva Pharmaceutical (TEVA) at 2.94% keep about the typical share of revenue as profit for their industries — neither bottom line stands out from peers.

Teva Pharmaceutical (TEVA) at 27.40% operates in the top operating margin quartile, ahead of Summit Therapeutics (SMMT) at 0.00%, which runs around its industry’s norm.

Profitability Metrics

Growth

Only one side can be read here: Teva Pharmaceutical (TEVA) reports revenue growth of 4.31%, ranked against its industry; Summit Therapeutics (SMMT) has no revenue growth figure this period.

Neither Summit Therapeutics (SMMT) nor Teva Pharmaceutical (TEVA) reports a EPS growth value for this period, so a direct comparison isn't possible.

Growth Metrics

Financial Strength

Summit Therapeutics (SMMT) at 5.99 keeps current ratio within its industry’s typical mid-range, while Teva Pharmaceutical (TEVA) at 0.95 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for TEVA.

Summit Therapeutics (SMMT) at 0.04 is near its industry mid-range for debt-to-equity ratio, while Teva Pharmaceutical (TEVA) at 2.13 sits above its benchmark range, pointing to a heavier debt load relative to equity.

Financial Strength Metrics

Dividends

Neither Summit Therapeutics (SMMT) nor Teva Pharmaceutical (TEVA) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Neither Summit Therapeutics (SMMT) nor Teva Pharmaceutical (TEVA) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Dividend Metrics

Valuation

An earnings multiple is available for just one side: Teva Pharmaceutical (TEVA) trades at 99.09 times trailing earnings, ranked against its peers, while Summit Therapeutics (SMMT) has no P/E ratio this period.

A sales-based read is only available for Teva Pharmaceutical (TEVA), whose P/S ratio of 2.89 ranks against industry peers; Summit Therapeutics (SMMT) reports no figure this period.

Teva Pharmaceutical (TEVA) at 6.23 sits near its industry’s typical P/B ratio, while Summit Therapeutics (SMMT) at 23.13 prices above its benchmark range — SMMT looks rich relative to book.

Valuation Metrics